Metraipolis › archive › dc_2e1e6ee6353d

Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis — Europe PMC PMID:42255919

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42255919
DOI
10.14309/crj.0000000000002173
License (as archived)
solo-consultazione
Archived
2026-10-31T19:50:52.195Z
SHA-256 of the archived text
55292007a87495deb6aebb2b47934a14041aec9f0a2d71976a885e858382dc55
Stable URL of this page
https://metraipolis.com/documento/dc_2e1e6ee6353d

How to cite

Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis — Europe PMC PMID:42255919 — Europe PMC (en), https://europepmc.org/article/MED/42255919 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2e1e6ee6353d (Metraipolis archive dc_2e1e6ee6353d, sha256 55292007a87495deb6aebb2b47934a14041aec9f0a2d71976a885e858382dc55)
BibTeX
@misc{dc2e1e6ee6353d,
  title = {Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis — Europe PMC PMID:42255919},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42255919},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2e1e6ee6353d; sha256 55292007a87495deb6aebb2b47934a14041aec9f0a2d71976a885e858382dc55},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42255919. Agents can read the archived copy with the MCP tool read_document.